Supernus, Inc. (INDV) stock analysis
Close on Oct 30, 2026Market cap $4.17BP/E 9.9Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak6 of 30 checks passed
Supernus passes 6 of the 30 checks behind our score; 20 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 3/6
- Past performance
- 2/6
- Financial health
- 1/6
- Dividend
- 0/6
What stands out
Revenue growing 10%+ a year
Revenue grew 11.2% a year over the last three fiscal years.
Interest well covered
Operating income covers interest expense 32.8 times.
Growing faster than the industry
Revenue grew 16.3% over the last twelve months; the Drugs median is 8.0%.
Gross margin improving
Gross margin was 85.0% over the last twelve months, against 80.5% a year earlier.
What to watch
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals 19.7% of total debt; we look for at least 20%.
Guidance lowered
Supernus lowered its Revised FY 2026 Guidance Total SUBLOCADE Net Revenue outlook on Aug 3, 2026.
Short-term assets don't cover short-term debts
Current assets are 0.61 times current liabilities.
No dividend
Supernus has not paid a dividend in the last twelve months.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth3/6
Revenue growing 10%+ a year
Revenue grew 11.2% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 16.3% over the last twelve months; the Drugs median is 8.0%.
Guidance lowered
Supernus lowered its Revised FY 2026 Guidance Total SUBLOCADE Net Revenue outlook on Aug 3, 2026.
Gross margin improving
Gross margin was 85.0% over the last twelve months, against 80.5% a year earlier.
Past performance2/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin above its 5-year average
Net margin was 32.8% over the last twelve months, against a 5-year average of 0.3%.
Net margin above the industry
Supernus's net margin of 32.8% is above the Drugs median of -53.0%.
Financial health1/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals 19.7% of total debt; we look for at least 20%.
Interest well covered
Operating income covers interest expense 32.8 times.
Short-term assets don't cover short-term debts
Current assets are 0.61 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Supernus has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Supernus. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $111.24M
- Value traded per 1% price move
- $46.10M
Downside
Medium risk
- Typical loss in a bad month
- 18.5%
- Volatility (annualized)
- 41%
- Sharpe ratio, 1 year
- -0.22
- Beta to the S&P 500 (5Y)
- 0.69
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2020 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.3% | +11.2% | – | – | |
| Gross profit | +3.9% | +9.9% | – | – | |
| Operating income | +589.5% | – | – | – | |
| Net income | +2900.0% | – | – | – | |
| EPS, diluted | +3180.0% | – | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -96.6% | |
| Return on assets | – | – | 16.7% | |
| Current ratio | – | – | 0.71 | |
| Debt to equity | – | – | -3.26 | |
| Net debt to EBITDA | – | – | 0.46× | |
| Interest coverage | – | – | 5.8× | |
| Inventory turnover | – | – | 1.5× | |
| Capex to revenue | – | – | 5.3% | |
| Diluted shares | – | – | 128M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Supernus generated $720.00M from operations and spent $520.00M on capital expenditure, dividends and share buybacks. 22% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 16.9% | 0.98× | -5.79× | -96.6% |
| FY2024 | 0.6% | 0.77× | -5.90× | -2.7% |
| FY2023 | -11.5% | 0.62× | -17.72× | 126.6% |
| FY2022 | -4.7% | 0.50× | 33.97× | -79.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$210.00M
- Cash generatingOperating cash flow above zero-$27.00M
- Return on assets improvedROA up on the prior year0.4% → 16.0%
- Earnings backed by cashOperating cash flow above net income-$27.00M vs $210.00M
- Less leverageLong-term debt to assets fell23.9% → 24.1%
- Better liquidityCurrent ratio rose0.90 → 0.71
- No dilutionShare count did not rise133M → 128M
- Gross margin improvedGross margin up on the prior year80.56% → 80.23%
- More efficientAsset turnover rose0.68 → 0.94
See a number that looks wrong?